Innate Pharma

Beleggen in aandelenbeurzen Europa: DAX, FTSE 100, CAC40, etc.



Gebruikersavatar
manu47
Premiummember
Premiummember
Berichten: 206
Lid geworden op: 11 apr 2013 13:35
waarderingen: 95

Re: Innate Pharma

Bericht door manu47 »

Mooie koersreactie vandaag door nieuws:

Innate Pharma advances lacutamab clinical development program
February 9, 2021 at 1:00 AM EST
PDF Version
Marseille, Feb. 09, 2021 (GLOBE NEWSWIRE) -- TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated

Company to initiate two new clinical trials to investigate lacutamab in peripheral T-cell lymphoma, including Phase 2 combination study with leading global lymphoma research network, LYSA

Webcast featuring key opinion leaders today at 2:00 p.m. CET / 8:00 a.m. ET

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced new clinical developments for its first-in-class, proprietary investigational asset, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. This includes advancement of the KIR3DL2-expressing mycosis fungoides (MF) cohort (cohort 2) to Stage 2 in the TELLOMAK study, as well as the initiation of the peripheral T-cell lymphoma (PTCL) clinical program.

Mycosis Fungoides: Advancing TELLOMAK Cohort 2 to Stage 2
In TELLOMAK, an open-label, multi-cohort, Phase 2 trial, lacutamab demonstrated a positive early signal in cohort 2. This cohort reached the pre-determined number of responses needed to advance to stage 2, allowing the Company to recruit additional patients. The Company plans to present this preliminary data at a scientific meeting in 2021.

Recruitment is ongoing in cohort 3, evaluating lacutamab as a monotherapy in KIR3DL2 non-expressing MF patients.

Peripheral T-Cell Lymphoma: Introducing a Data-Driven Clinical Strategy
The Company today announced plans to initiate two parallel clinical trials to study lacutamab in KIR3DL2-expressing patients with relapsed/refractory PTCL. Together these trials offer a data-driven strategy to identify potential opportunities for lacutamab in the relapsed setting, and potential expansion into earlier lines of therapy for PTCL in the future.

Phase 1b trial: a Company-sponsored Phase 1b clinical trial to evaluate lacutamab as a monotherapy in KIR3DL2-expressing patients with relapsed PTCL.

Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial: The Lymphoma Study Association (LYSA) will launch an investigator-sponsored, randomized trial to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine in combination with oxaliplatin) versus GEMOX alone in KIR3DL2-expressing relapsed/refractory patients.
“Lacutamab is our priority clinical asset, and we are pleased to share important progress of this program. The early signal seen in the KIR3DL2-expressing mycosis fungoides patient population is encouraging and moves us past the pre-determined threshold for the cohort earlier than anticipated,” said Joyson Karakunnel, M.D., MSc, FACP, Chief Medical Officer Innate Pharma. “In addition, our PTCL trials announced today demonstrate our strategy to first explore lacutamab’s potential in the relapsed/refractory setting, then potentially in earlier lines of treatment. Partnering with LYSA will provide invaluable expertise given their track record in advancing therapeutics for the lymphoma community.”

“Relapsed PTCL patients are in need of alternative, effective options and we are pleased to partner with Innate Pharma on this important study,” said Franck Morschhauser, Professor of Hematology in Lille (France) and President of LYSA. “KIR3DL2 represents a meaningful target, as it is expressed in up to 50% of PTCL across subtypes. Through our global network and deep expertise in lymphoma, we believe this study will help us better understand the potential for lacutamab to help these patients.”

To learn more about these updates, join Innate’s executive leadership team, as well as Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Jefferson University Hospital and principal investigator of Innate’s Phase 2 TELLOMAK study, and Olivier Hermine, M.D., Professor of Hematology at the University of Paris Descartes, Director, Division of Adult Hematology at Hôpital Universitaire Necker Enfants Malades and principal investigator of the LYSA Phase 2 KILT study for a virtual presentation today.

Webcast and conference call will be held today at 2:00 p.m. CET / 8:00 a.m. ET

Access to live webcast: https://edge.media-server.com/mmc/p/yztsebvs

Participants may also join via telephone by registering in advance of the event at http://emea.directeventreg.com/registration/2284358. Upon registration, participants will be provided with dial-in numbers, a direct event passcode and a unique registrant id that they may use 10 minutes prior to the event start to access the call.

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

About Lacutamab:

Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with peripheral t-cell lymphoma (PTCL). It has a restricted expression on normal tissues.

About TELLOMAK:

TELLOMAK is a global, open-label, multi-cohort Phase 2 clinical trial recruiting patients with advanced T-cell lymphomas (TCL) in the United States and Europe. TELLOMAK is expected to recruit up to 150 patients, with lacutamab evaluated:

As a single agent in approximately 60 patients with Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab.
As a single agent in approximately 90 patients with mycosis fungoides (MF) who have received at least two systemic therapies.
In patients with MF, the study is designed to evaluate the benefit of lacutamab according to KIR3DL2 expression. The study comprises two cohorts in MF, testing lacutamab in KIR3DL2 expressing and non-expressing patients determined at baseline. These cohorts follow a Simon 2-stage design that will terminate early if treatment is considered futile. The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication.

The primary endpoint of the trial is objective response rate. Key secondary endpoints are progression-free survival, duration of response, quality of life and adverse events.

About Lacutamab in PTCL:

Two clinical trials will investigate lacutamab in KIR3DL2-expressing PTCL patients who have received at least one prior systemic therapy. Lacutamab is being evaluated:

In a multi-center, Phase 1b clinical trial as a single agent in approximately 20 relapsed patients expressing KIR3DL2. The trial is designed to evaluate safety, as well as characterize clinical outcomes, pharmacokinetics and immunogenicity of lacutamab alone in PTCL. Further expansion will be determined based on preliminary efficacy signals.
In a multi-center, randomized Phase 2 trial in combination with GEMOX in relapsed/refractory patients expressing KIR3DL2. This study will include approximately 60 patients. The combination trial, KILT (anti-KIR in T-Cell Lymphoma), is being conducted by the Lymphoma Study Association (LYSA) and its operational organization Lymphoma Academic Research Organisation (LYSARC); it will evaluate the efficacy and safety of lacutamab in combination with chemotherapy GEMOX in prescreened patients, with progression-free survival as the primary endpoint.
About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code
Ticker code
LEI FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29


Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors
Innate Pharma
Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com

Media
Innate Pharma
Tracy Rossin (Global/US)
Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com
NewB76 liked last!
Value (80%): C50, IWDA, CP9, CJ1, Mytilineos, EVS, Moury Constr, CK Asset, NN, NBB, Ageas, Econocom, Smartphoto, Orange Bel, iA Financial, Qiwi, Alpha Pro
Speculatief (20%): , Ontex, NEL, Innate, Biocartis, KKO, Exmar, Acacia, Transgene, Pharming, Celyad, SPCE, Sorrento, IBA, Photonike



gigagoeroe
Forum actieveling
Forum actieveling
Berichten: 895
Lid geworden op: 11 okt 2012 20:17
waarderingen: 388

Re: Innate Pharma

Bericht door gigagoeroe »

Geen onaangename verrassingen, wat voor Innate alvast een prettige wending is.
Kostenplaatje met 15% naar beneden (kan nooit kwaad).
Recrutering Phase 2 FORCE (FOR COVID-19 Elimination) beëindigd, is ook leuk.

Innate Pharma reports Full Year 2020 financial results and business update
• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma
• Company’s first NK cell engager selected by Sanofi as drug candidate for development
• Monalizumab advanced to a Phase 3 clinical trial in combination with cetuximab in IO-pretreated head and neck cancer patients; triggered $50 million milestone payment from AstraZeneca
• US and EU Lumoxiti commercialization rights returning to AstraZeneca
• Cash position of €190.6 million[1] as of December 31, 2020

Marseille, France, March 18, 2021
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the year ending December 31, 2020. The consolidated financial statements are attached to this press release.

“In 2020, we made the strategic decision to re-prioritize our investments in our R&D portfolio, enabling us to concentrate our resources and further strengthen our clinical pipeline,” commented Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. “Our priority going forward is to advance the clinical development of our lead proprietary candidate, lacutamab, as well as leverage our multispecific NKCE antibody platform, to create potential innovative therapeutics for patients and provide long-term value to our shareholders.”
________________________________________
Financial highlights for 2020:
The key elements of Innate’s financial position and financial results as of and for the year ended December 31, 2020 are as follows:
• Cash, cash equivalents, short-term investments and financial assets amounting to €190.6 million (€m) as of December 31, 2020 (€255.9m as of December 31, 2019), including non-current financial instruments amounting to €38.9m (€37.0m as of December 31, 2019).
o Cash and cash equivalents include the milestone payment of $50.0m (€41.2m) following the inclusion by AstraZeneca of the first patient in its Phase 3 randomized clinical trial evaluating monalizumab, INTERLINK-1. It doesn’t include the milestone payment of €7.0m from Sanofi relating to the progress of IPH6101/SAR443579 into new drug (IND)-enabling studies, received in February 2021.
• As of December 31, 2020, financial liabilities amount to €19.1m (€18.7m as of December 31, 2019). This change is partly linked to the receipt, in August 2020, of €1.4m in repayable advance in connection with the financing contract signed with BPI Financement (COVID-19).
• Revenue and other income amounted to €70.5m in 2020 (2019: €85.8m, -17.9%). It mainly comprises revenue from collaboration and licensing agreements (€56.2m in 2020 vs €69.0m in 2019, -18.6%), and research tax credit (€13.1m in 2020 vs €16.7m in 2019, -21.8%):
o Revenue from collaboration and licensing agreement with AstraZeneca amounted to €49.0m in 2020 (€69.0m in 2019, -29.0%) and mainly resulted from (i) the spreading of the upfront and opt-in payments received from AstraZeneca and (ii) the invoicing to AstraZeneca of certain fees for the work performed by Innate for the partnered programs. The variation between the two periods is notably explained by the completion of (i) the recruitment of the Cohort 2 in the monalizumab Phase 2 trials performed by Innate in 2019, and (ii) the preclinical work related to the Phase 1 program of IPH5201, which started in 2020.
o Revenue of €7.0m from Sanofi for the progress of IPH6101/SAR443579 into investigational new drug (IND)-enabling studies.
o The variation in the research tax credit mainly results from a decrease in the amortization for the intangible assets related to acquired licenses (monalizumab, IPH5201).
• Operating expenses of €89.9m in 2020 (2019: €104.6m, -14.1%):

o Selling, general and administrative (SG&A) expenses amounted to €31.2m in 2020 (2019: €25.8m, +21.1%). This increase mainly results from the full-year effect of personnel costs related to our US subsidiary, including personnel assigned to Lumoxiti commercial activities.
o R&D expenses amounted to €58.6m in 2020 (2019: €78.8m, -25.7%). This variation mainly results from a decrease in direct R&D expenses (mainly related to Lumoxiti, IPH5201 and IPH5301) and in depreciation and amortization of intangible assets acquired by the Company (IPH5201 and monalizumab).
• Lumoxiti intangible asset full impairment of €43.5m, following the Company's decision to return the US and EU commercialization rights of Lumoxiti to AstraZeneca.
• The Lumoxiti distribution agreement generated a net income of €0.9m in the first three quarters of 2020 (a net loss of €8.2m in 2019). During the 2020 fourth quarter, the Company recognized net sales from Lumoxiti of €0.7m.
• A net loss of €64.0m in 2020 (2019: net loss of €20.8m).

________________________________________
[1] Including short term investments (€14.8m) and non-current financial instruments (€38.9m).

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 922
Lid geworden op: 30 mei 2018 21:25
waarderingen: 421

Re: Innate Pharma

Bericht door And its gone! »

Nog sukkelaars die dit aandeel in port hebben?
Ik denk eraan met 46% verlies te verkopen...

Gebruikersavatar
manu47
Premiummember
Premiummember
Berichten: 206
Lid geworden op: 11 apr 2013 13:35
waarderingen: 95

Re: Innate Pharma

Bericht door manu47 »

Yep, 5.98 als aankoopprijs. Had ze aangekocht omdat ze 1 kwartaal winst hebben gemaakt, staat gecatalogiseerd als beginnersfout en gelukkig kleine positie. Daarom verkoop ik ook niet, zou niet de eerste keer zijn dat ze dan dag nadien met goed nieuws PB komen.
Value (80%): C50, IWDA, CP9, CJ1, Mytilineos, EVS, Moury Constr, CK Asset, NN, NBB, Ageas, Econocom, Smartphoto, Orange Bel, iA Financial, Qiwi, Alpha Pro
Speculatief (20%): , Ontex, NEL, Innate, Biocartis, KKO, Exmar, Acacia, Transgene, Pharming, Celyad, SPCE, Sorrento, IBA, Photonike

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 922
Lid geworden op: 30 mei 2018 21:25
waarderingen: 421

Re: Innate Pharma

Bericht door And its gone! »

manu47 schreef:
06 mei 2021 17:12
Yep, 5.98 als aankoopprijs. Had ze aangekocht omdat ze 1 kwartaal winst hebben gemaakt, staat gecatalogiseerd als beginnersfout en gelukkig kleine positie. Daarom verkoop ik ook niet, zou niet de eerste keer zijn dat ze dan dag nadien met goed nieuws PB komen.
Ik hoop voor jou dat er een knaller van een pb komt. Ik heb alles verkocht, hopeloze zaak in mijn ogen, en met al die bio's momenteel goedkoop veel betere opportuniteiten. GLTA!

bertje
Forum elite
Forum elite
Berichten: 7480
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1736

Re: Innate Pharma

Bericht door bertje »


Brammeke
Forum veteraan
Forum veteraan
Berichten: 1266
Lid geworden op: 19 okt 2016 15:33
waarderingen: 545

Re: Innate Pharma

Bericht door Brammeke »

Nieuwe Lacutamab-gegevens van TELLOMAK-studie worden gepresenteerd in mondelinge presentatie op de komende 16e internationale conferentie over maligne lymfoom‎
Nieuws via RSS voor Innate Pharma
09 juni 2021 12:00
‎Eerste klinische gegevens van mycose fungoides gepresenteerd uit de TELLOMAK studie‎

‎Marseille, Frankrijk, 09 juni 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("‎‎Aangeboren‎‎" of het "‎‎Bedrijf‎‎") heeft vandaag aangekondigd dat voorlopige mycose fungoides gegevens van de Fase 2 TELLOMAK studie die lacutamab evalueert, een anti-KIR3DL2 cytotoxiciteit-inducerend antilichaam in ontwikkeling voor T-cel lymfomen, zal worden gepresenteerd tijdens een mondelinge presentatie op de virtuele‎‎16e‎‎ Internationale Conferentie over Maligne Lymfoom (16-ICML) die plaatsvindt van 18-2 juni.‎

‎Details van de mondelinge presentatie: ‎

‎Titel:‎‎ ‎‎Lacutamab bij patiënten met gevorderde mycose fungoides volgens KIR3DL2 expressie: vroege resultaten van de TELLOMAK fase 2 studie‎

‎Datum en tijd:‎‎ 22 juni 2021 om 13.m CEST‎

‎Abstract getal:‎‎ 054‎

‎Tellomak trial investigator, Martine Bagot, M.D., Ph.D., Professor of Dermatology, Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, zal de mondelinge presentatie geven. ‎

‎Pr. Bagot zal de gegevens ook presenteren tijdens een online webcast van Innate Pharma voor de financiële gemeenschap op 23 juni 2021. Details over deze webcast zullen uiterlijk op 16 juni 2021 op de website van het bedrijf worden verstrekt.‎

‎Over Lacutamab:‎

‎Lacutamab (IPH4102) is een eersteklas anti-KIR3DL2 gemenselijkd cytotoxiciteitsopwekkend antilichaam, dat momenteel in klinische studies wordt uitgevoerd voor de behandeling van cutaan T-cellymfoom (CTCL), een weesziekte. Deze groep zeldzame cutane lymfomen van T-lymfocyten heeft een slechte prognose met weinig effectieve en veilige therapeutische opties in gevorderde stadia. ‎

‎KIR3DL2 is een remmende receptor van de KIR-familie, uitgedrukt door ongeveer 65% van de patiënten in alle CTCL-subtypen en uitgedrukt door maximaal 90% van de patiënten met bepaalde agressieve CTCL-subtypes, met name het syndroom van Sézary. Het wordt uitgedrukt door maximaal 50% van de patiënten met mycose fungoides en perifeer t-cellymfoom (PTCL). Het heeft een beperkte expressie op normale weefsels.‎

‎Over TELLOMAK:‎

‎TELLOMAK is een wereldwijd, open-label, multi-cohort fase 2 klinische studie die patiënten met gevorderde T-cel lymfomen (TCL) rekruteert in de Verenigde Staten en Europa. TELLOMAK zal naar verwachting tot 150 patiënten werven, waarbij lacutamab wordt geëvalueerd:‎

‎Als enkelvoudig middel bij ongeveer 60 patiënten met het syndroom van Sézary die ten minste twee eerdere systemische therapieën hebben gekregen, waaronder mogamulizumab.‎
‎Als enkelvoudig middel bij ongeveer 90 patiënten met mycose fungoides (MF) die ten minste twee systemische therapieën hebben gekregen.‎
‎Bij patiënten met MF is de studie ontworpen om het effect van lacutamab te evalueren volgens kir3DL2-expressie. De studie omvat twee cohorten in MF, waarbij lacutamab in KIR3DL2-uitdrukkende en niet-uitdrukkende patiënten worden getest die bij aanvang zijn bepaald. Deze cohorten volgen een Simon 2-traps ontwerp dat vroegtijdig zal eindigen als de behandeling als nutteloos wordt beschouwd. Het Sézary-syndroomcohort van de studie zou de registratie van lacutamab in deze indicatie mogelijk kunnen maken. ‎

‎Het primaire eindpunt van de studie is het objectieve responspercentage. Belangrijke secundaire eindpunten zijn progressievrije overleving, duur van de respons, kwaliteit van leven en bijwerkingen.‎

Brammeke
Forum veteraan
Forum veteraan
Berichten: 1266
Lid geworden op: 19 okt 2016 15:33
waarderingen: 545

Re: Innate Pharma

Bericht door Brammeke »

INNATE PHARMA PRESENTEERT NIEUWE DATA OVER NEXT-GENERATION NK CELL ENGAGER PLATFORM OP FOCIS 2021 JAARVERGADERING

do, 06/10/2021 - 07:00

Gepatenteerd, multi-specifiek NK-cel engagerplatform, ANKET™, om de volgende golf van immunotherapiemoleculen te genereren
ANKET is de eerste NK-cel engagertechnologie die NKp46, CD16, IL 2-variant en tumorantigeen in één tetraspecifiek molecuul inzetten
De preklinische gegevens van vandaag benadrukken robuuste antitumoreffectiviteit in verschillende in vivo tumormodellen en een beheersbaar veiligheidsprofiel
Aangeboren om de gegevens te laten zien in het komende virtuele IR R&D-evenement op woensdag 23 juni
Innate Pharma SA (Euronext Parijs: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" of het "Bedrijf") kondigde aan dat het de nieuwste preklinische gegevens van zijn volgende generatie, gepatenteerde, multi-specifieke NK-cel engager platform bekend als ANKET™ (Eenop ntibody gebaseerde NK-cel Engager Therapeutics) zal presenteren op de Federation of Clinical Immunology Societies (FOCIS) vergadering. De presentatie vindt vandaag om 19.00 uur CEST plaats.

In het bijzonder zal Innate nieuwe gegevens delen van zijn tetraspecifieke ANKET-molecuul, de eerste NK-cel engagertechnologie die activerende receptoren (NKp46 en CD16), een tumorantigeen en een cytokine (IL-2-variant) in één molecuul aanneemt. Deze nieuwste innovatie maakt gebruik van de voordelen van het benutten van NK-celeffectorfuncties tegen kankercellen en biedt ook proliferatie- en activeringssignalen gericht op NK-cellen. Deze dataset is gebaseerd op de bestaande tri-specifieke NK-cel engagertechnologie van Innate, die krachtige NK-celactivatie, cytotoxiciteit en efficiënte controle van tumorgroei in preklinische modellen heeft aangetoond.

In preklinische studies toonde tetraspecifieke ANKET in vitro het vermogen aan om menselijke NK-celproliferatie, cytokineproductie en cytolytische activiteit tegen kankercellen te induceren die het beoogde antigeen uitdrukken. Tetra-specifieke ANKET toonde ook in vivo antitumor werkzaamheid in verschillende tumormodellen, waardoor regressie van gevestigde tumoren en controle van metastase, geassocieerd met verhoogde NK celinfiltratie, cytokine en chemokine productie op de tumor site. ANKET vertoonde ook een farmacodynamisch effect, een lage systemische cytokine-afgifte en een beheersbaar veiligheidsprofiel bij niet-menselijke primaten.

"We zijn verheugd om de nieuwe evolutie van ons ANKET-platform vandaag te introduceren op de FOCIS-bijeenkomst", aldus Pr. Eric Vivier, PhD, DVM, Chief Scientific Officer bij Innate Pharma. "NK-cellen spelen een cruciale rol in de aangeboren immuniteitscyclus van kanker, en het betrekken ervan is een opwindend pad om het therapeutische venster voor kankerbehandeling te verbeteren in vergelijking met T-cel engagers. Wij geloven dat de nieuwe bevindingen verkregen met onze ANKET-technologie het potentieel ervan vastleggen om zinvolle resultaten voor patiënten te bevorderen. Deze vooruitgang stelt ons in staat om een geheel nieuwe klasse moleculen te creëren om synthetische immuniteit tegen kanker op te wekken. We kijken ernaar uit om extra details te delen op ons komende IR R&D-evenement."

Innate's belangrijkste ANKET-asset, IPH6101 (SAR443579), heeft antitumoractiviteit aangetoond in preklinische modellen, waaronder het aanmoedigen van farmacokinetische, farmacodynamische en veiligheidsgegevens in voorlopige niet-menselijke primatenstudies. In januari nam Sanofi de beslissing om dit programma voort te zetten in onderzoeken naar nieuwe geneesmiddelen (IND)-achtige studies. Als onderdeel van de eerder aangekondigde onderzoekssamenwerking werken de bedrijven momenteel ook aan het tweede onderzoeksprogramma.

Innate zal meer informatie geven over de gegevens van vandaag tijdens een aanstaande online R&D-presentatie voor de beleggersgemeenschap die gepland staat voor 14.m CEST op 23 juni 2021.

Over ANKET™

ANKET™ (Eenop ntibody gebaseerde NK-cel Engager Therapeutics) is het gepatenteerde platform van Innate Pharma voor het ontwikkelen van multispecifieke NK-cel engagers voor de behandeling van bepaalde soorten kanker. De nieuwste innovatie van het bedrijf, het tetraspecifieke ANKET-molecuul, is de eerste NK-cel engagertechnologie die activerende receptoren (NKp46 en CD16), een tumorantigeen en een cytokine (IL-2v) in één molecuul activeert. Dit maakt gebruik van de voordelen van het benutten van NK-celeffectorfuncties tegen kankercellen en biedt ook proliferatie- en activeringssignalen gericht op NK-cellen.

In preklinische studies heeft de tri- en tetraspecifieke technologie van Innate krachtige NK-celactivatie, cytotoxiciteit en efficiënte controle van tumorgroei in preklinische modellen aangetoond. Deze veelzijdige fit-for-purpose technologie creëert een geheel nieuwe klasse moleculen om synthetische immuniteit tegen kanker op te wekken.









Plaats reactie